Full-Time

Associate Director

Real World Data Science

Updated on 9/4/2026

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$169.2k - $253k/yr

+ Incentive opportunity

Rockville, MD, USA + 1 more

More locations: Princeton, NJ, USA

In Person

Approximately 10% travel, including international travel, is required.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
SAS
Data Science
R
Machine Learning
Electronic Health Records (EHR)
AWS
Data Analysis

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • Three to five years of experience in outcomes research methods and analysis, with strong expertise in non-interventional study designs and statistical analyses.
  • Comprehensive understanding of the healthcare industry, including pharmaceutical research and development, clinical research, commercialization, health technology assessment bodies, managed care marketplace, hospital systems, and integrated systems of care.
  • Proficiency in statistical programming using SAS and the AWS environment, with experience in machine learning and artificial intelligence applications.
  • Ability to independently develop research hypotheses, study protocols, and statistical analysis plans, with knowledge of epidemiology, economics, psychometrics, and medical writing.
  • Strong understanding of administrative claims data, electronic medical records, hospital inpatient data, and survey data, including their applications and limitations.
  • Proven ability to manage complex projects involving multiple external vendors.
  • Experience working with and overseeing external contractors and vendors, with the ability to understand and respond to customer and payer requests and develop value dossiers.
  • PhD or Master's degree in Health Economics, Outcomes Research, Health Services Research, Public Health, or a related discipline.
  • Three years of relevant experience for a PhD holder or five years of relevant experience for a Master's holder.
Responsibilities
  • Partner with Value Evidence Strategy to design and lead analytical studies and programming for real-world evidence analysis plans supporting value and scientific evidence generation.
  • Work closely with Value Evidence and Global Medical Affairs teams to support value and scientific evidence generation across Otsuka's product portfolio.
  • Apply fit-for-purpose traditional or novel methodologies, including artificial intelligence and machine learning methodologies, in data and statistical techniques, stay current with new analytical approaches, and collaborate with subject matter experts to design and deliver medically relevant and scientifically valid projects.
  • Co-lead study protocol development and database query guidelines for internal datasets, overseeing internal analyses to support studies.
  • Serve as the interface supporting pharmacoeconomic and real-world data needs across various departments.
  • Co-lead the preparation and review of study protocols and reports for internal datasets, including statistical analysis plans, and manage associated vendors as appropriate.
  • Manage department-specific data licensing and platform needs, oversee vendors, and ensure compliance with licensing terms.
  • Identify appropriate United States and international databases for licensing to address research questions and align with therapeutic area strategy.
  • Participate in establishing external partnerships and work on all scientific aspects of projects involving these partnerships.
  • Present analytics for health outcomes projects and information to internal and external groups, including regulatory authorities, key opinion leaders, and at medical and outcomes research conferences.
  • Participate in publication planning and execution, coordinating with Otsuka Scientific Communications personnel and Value Evidence Strategy.
  • Support preparation of medical or payer advisory meetings to solicit feedback on Otsuka products and therapeutic areas.
  • Identify and support projects that directly support the economic and quality strategy for Otsuka products.
  • Support development of product dossiers and other projects supporting different aspects of formulary submissions.
  • Manage budget resources allocated to assigned projects.
  • Assist in developing educational material for internal and external audiences, including payer communication field tools, when appropriate.
  • Maintain awareness of current strategies, issues, and new data sources, ensuring compliance with all guidelines and best practices for scientific research.
Desired Qualifications
  • Experience with R is preferred.
  • Willingness to travel approximately 10%, including international travel, for conferences, corporate locations, and stakeholder meetings.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.